Quantum Biopharma licensee to hold webinar Sept. 16

Mr. Zeeshan Saeed reports QUANTUM BIOPHARMA LICENSEE UNBUZZD WELLNESS TO HOST INVESTOR WEBINAR ON SEPTEMBER 16, 2025 AT 1:30 PM PT Quantum Biopharma Ltd. licensee Unbuzzd Wellness Inc. will host an investor webinar on Tuesday, Sept. 16, 2025, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Standard Time). During the webinar, Unbuzzd chief executive officer John Duffy, adviser Jason Sawyer, medical director Dr. Eric Hoskins and board co-chair Gerry David will discuss the current Regulation D 506(c) investment opportunity for its scientifically proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms. Investors will also learn about Unbuzzd Wellness's strategies to accelerate direct-to-consumer, distributor and retail sales. A question-and-answer session will follow the presentation. Mr. Duffy commented: "We look forward to this opportunity to engage and inform current and potential investors about the rapidly expanding global market for Unbuzzd. We will review the science behind how it works and discuss results from our double-blind, placebo-controlled clinical study. We will also discuss the current opportunity to invest in our Regulation D 506(c) offering, where we expect to raise up to $5-million (U.S.) to support our aggressive expansion plans and possible initial public offering." Quantum Biopharma shareholders will not be diluted by this offering. A replay of the webinar will be available upon request by contacting [email protected] or by calling 518-862-5993. About Unbuzzd Wellness Inc. Unbuzzd Wellness, a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. Unbuzzd has been developed by a world-class R&D (research and development) team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals and herbs, Unbuzzd helps your body process alcohol faster, restore mental alertness and improve cognition so you can drink responsibly and drink refreshingly. Unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control and still feel great the next day. Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, Unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration (BAC), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include: Accelerated alcohol metabolism: Unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 per cent faster within 30 minutes of consuming Unbuzzd compared with control subjects. Rapid improvements in alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming Unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming Unbuzzd, significantly outperforming placebo results. Rapid improvements in physiologic changes due to intoxication: Unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant. Reduced perceived impairment and mental fatigue: Unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication. Hangover relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment and reduced headache compared with placebo results, at both four hours (67-per-cent reduction in headache severity) and eight hours after consuming Unbuzzd. No side effects: Unbuzzd was well tolerated by all study participants, with no reported adverse side effects. Unbuzzd ready-to-mix powder sticks are available in three-pack, eight-pack and 18-pack formats on the Unbuzzd website. Individual results may vary. Unbuzzd is a dietary supplement. Consuming Unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. Do not drink and drive. About Quantum Biopharma Ltd. Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma invented Unbuzzd and spun out its OTC (over-the-counter) version to a company, Celly Nutrition Corp., now Unbuzzd Wellness, led by industry veterans. Quantum Biopharma retains ownership of 20.10 per cent (as of June 30, 2025) of Unbuzzd Wellness. The agreement with Unbuzzd Wellness also includes royalty payments of 7 per cent of sales from Unbuzzd until payments to Quantum Biopharma total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum Biopharma retains 100 per cent of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum Biopharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., representing loans secured by residential or commercial property. We seek Safe Harbor.